Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2007-06-12
2007-06-12
Campell, Bruce R. (Department: 1648)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S387100, C530S387700
Reexamination Certificate
active
10259853
ABSTRACT:
Multivalent, multispecific molecules having at least one specificity for a pathogen and at least one specificity for the HLA class II invariant chain (Ii) are administered to induce clearance of the pathogen. In addition to pathogens, clearance of therapeutic or diagnostic agents, autoantibodies, anti-graft antibodies, and other undesirable compounds may be induced using the multivalent, multispecific molecules.
REFERENCES:
patent: 3927193 (1975-12-01), Hansen et al.
patent: 4331647 (1982-05-01), Goldenberg
patent: 4348376 (1982-09-01), Goldenberg
patent: 4361544 (1982-11-01), Goldenberg
patent: 4460561 (1984-07-01), Goldenberg
patent: 4468457 (1984-08-01), Goldenberg et al.
patent: 4624846 (1986-11-01), Goldenberg
patent: 4671958 (1987-06-01), Rodwell et al.
patent: 4699784 (1987-10-01), Shih et al.
patent: 4818709 (1989-04-01), Primus et al.
patent: 4925648 (1990-05-01), Hansen et al.
patent: 4932412 (1990-06-01), Goldenberg
patent: 6018031 (2000-01-01), Shen et al.
patent: 0 308 208 (1989-03-01), None
patent: 0 308 208 (1989-03-01), None
patent: WO 92/19273 (1992-11-01), None
patent: WO 97/23237 (1997-07-01), None
Hansen, et al. Internalization and Catabolism of radiolabelled antibodies to the MHC class-II invatiant chain by B-cell lymphomas. Biochem. Journal 1996 ol 320, pp. 293-300.
Hansen,Biochem. J. (1996), vol. 320, pp. 293-300.
Cardenas et al.,Infection and Immunity(1993), vol. 61, pp. 4629-4636.
Hosmalin et al.,PNAS(1990), vol. 87, pp. 2344-2348.
Hansen et al., Internalization and Catabolism of Radiolabelled Antibodies to the MHC Class-II Invariant Chain by 8-Cell Lymphmas,Biochemical Journal(Nov. 15, 1996), vol. 320, pp. 293-300, XP-002110872.
Gautherot et al., “Therapy for Colon Carcinoma Xenografts with Bispecific Antibody-Targeted, Lodine-131-Labeled Bivalent Hapten,”Cancer(Dec. 15, 1997), vol. 80, pp. 2618-2623, XP-002110873.
Karacay et al., “Development of a Streptavidin-anti-Carcinoembyronic Antigen Antibody, Readiolabeled Biotin Pre-targeting Method for Radioimmunotherapy of Colorectal Cancer. Reagent Development,”Bioconjugate Chemistry(Jul.-Aug. 1997), vol. 8, No. 4, pp. 585-594, XP-002110874.
Elsasser, David, et al., “HLA Class II as Potential Target Antigen on Malignant B Cells for Therapy with Bispecific Antibodies in Combination with Granulocyte Colony-Stimulating Factor” Blood, vol. 87, No. 9 (May 1, 1996: pp. 3803-3812.
Mezzanzanica, Delia, et al., “Retargeting of Human Lymphocytes Against Human Ovarian Carcinoma Cells by Bispecific Antibodies: from laboratory to Clinic” Int. J. Clin. Lab Res 21:159-164, 1991.
Campell Bruce R.
Faegre & Benson LLP
Hill Myron G.
Immunomedics Inc.
LandOfFree
Therapeutic using a bispecific antibody does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Therapeutic using a bispecific antibody, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic using a bispecific antibody will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3853525